CORT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Corcept Therapeutics Inc (CORT) is not a strong buy for a beginner, long-term investor at this time. The stock faces significant legal challenges, declining financial performance, and bearish technical indicators. Despite some positive catalysts like strong gross margins and potential growth in ovarian cancer treatments, the overall sentiment and risks outweigh the potential rewards for a long-term investment strategy.
The stock is showing bearish momentum with SMA_200 > SMA_20 > SMA_5, indicating a downward trend. RSI is neutral at 36.554, and MACD is slightly positive but not strong enough to signal a reversal. Key support is at 30.868, and resistance is at 40.181, suggesting limited upside in the near term.
Strong gross margin of 98.74%, up 0.38% YoY.
Positive Phase III ROSELLA trial data for ovarian cancer treatment, which could drive future growth.
Analysts maintain Buy ratings despite price target reductions, showing some confidence in the company's long-term potential.
Multiple class action lawsuits related to alleged misrepresentation of clinical evidence and FDA rejection of relacorilant NDA.
Declining financial performance with a 21% drop in net income and a 26.92% drop in EPS YoY in Q4
Bearish technical indicators and weak trading sentiment.
Downgrades and reduced price targets from analysts, with Wolfe Research assigning an Underperform rating and a $30 price target.
In Q4 2025, revenue increased by 11.12% YoY to $202.13M, but net income dropped by 21% YoY to $24.29M, and EPS fell by 26.92% YoY to 0.19. While gross margins remain strong, declining profitability and earnings are concerning.
Analysts maintain Buy ratings but have significantly lowered price targets due to FDA setbacks and legal challenges. Recent price targets range from $30 (Wolfe Research) to $100 (Canaccord), reflecting mixed confidence in the stock's future performance.
